Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Changes in serum leptin levels during GnRH agonist therapy.

Tsutomu Douchi1, Tomoki Kuwahata, Nobuyuki Yoshimitsu

  • 1Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan.

Endocrine Journal
|August 28, 2003
PubMed
Summary

Gonadotropin-releasing hormone (GnRH) agonist therapy for uterine fibroids did not significantly alter serum leptin levels. Body fat increased and lean mass decreased, but the leptin-fat mass ratio remained stable.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in Quality of Life, Depression, and Menopausal Symptoms After Surgical Menopause and the Efficacy of Hormone Replacement Therapy in Gynecological Cancer Survivors: A One-Year Prospective Longitudinal Study.

Medicina (Kaunas, Lithuania)·2025
Same author

Predicting postpartum depression by evaluating temperament during pregnancy.

Journal of affective disorders·2021
Same author

The Optimal Cutoff Level of D-Dimer during Pregnancy to Exclude Deep Vein Thrombosis, and the Association between D-Dimer and Postpartum Hemorrhage in Cesarean Section Patients.

The Kurume medical journal·2021
Same author

Menstrual restoration in severe panhypopituitarism many years after cranial irradiation for suprasellar germinoma.

Reproductive medicine and biology·2017
Same author

Weight reduction using a formula diet recovers menstruation in obese patients with an ovulatory disorder.

Reproductive medicine and biology·2017
Same author

Multivariate curve resolution using a combination of mid-infrared and near-infrared spectra for the analysis of isothermal epoxy curing reaction.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2017

Area of Science:

  • Endocrinology
  • Reproductive Medicine
  • Metabolic Research

Background:

  • Leptin, a key hormone in energy balance and metabolism, is influenced by sex hormones.
  • Gonadotropin-releasing hormone (GnRH) agonists are used to treat conditions like uterine leiomyomas by suppressing ovarian function.
  • Understanding leptin dynamics during GnRH agonist therapy is crucial for managing metabolic changes in patients.

Purpose of the Study:

  • To investigate the impact of GnRH agonist therapy on serum leptin levels in women with uterine leiomyomas.
  • To assess changes in body composition, including fat mass and lean mass, during this therapy.
  • To evaluate the relationship between leptin, body composition, and hormonal changes induced by GnRH agonists.

Main Methods:

  • A cohort of 20 women with uterine leiomyomas received monthly GnRH agonist (leuprorelin acetate) injections for 4 months.

Related Experiment Videos

  • Serum leptin and estradiol levels were measured before and after therapy.
  • Body composition (weight, fat mass, lean mass) was assessed using dual-energy X-ray absorptiometry (DXA).

    • Main Results:

    • GnRH agonist therapy led to amenorrhea and a significant decrease in estradiol levels.
    • Serum leptin levels showed no significant change from baseline after 4 months of therapy.
    • Total body fat mass increased significantly, while total body lean mass decreased significantly.
    • The leptin-to-fat mass ratio remained unchanged, indicating leptin levels adjusted proportionally to fat mass changes.

    Conclusions:

    • GnRH agonist-induced hypogonadism does not appear to significantly impact circulating leptin levels.
    • Changes in body fat and lean mass occur during GnRH agonist therapy, but leptin levels remain relatively stable in relation to fat mass.
    • These findings suggest that leptin regulation is robust and not solely dependent on short-term hormonal fluctuations induced by GnRH agonists.